Matches in SemOpenAlex for { <https://semopenalex.org/work/W2750528063> ?p ?o ?g. }
- W2750528063 endingPage "834" @default.
- W2750528063 startingPage "828" @default.
- W2750528063 abstract "It has been demonstrated that androgen receptor splice variant 7 (AR-V7) expression in circulating tumor cells (CTCs) predicts poor treatment response in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone or enzalutamide. To develop a practical and robust liquid profiling approach for direct quantification of AR-V7 in peripheral whole blood without the need for CTC capture and to determine its potential for predicting treatment response in mCRPC patients. Whole blood samples from a prospective biorepository of 85 mCRPC patients before treatment initiation with abiraterone (n = 56) or enzalutamide (n = 29) were analyzed via droplet digital polymerase chain reaction. The association of AR-V7 status with prostate-specific antigen (PSA) response defined by PSA decline ≥50% and with PSA–progression-free survival (PSA-PFS), clinical PFS, and overall survival (OS) was assessed. High AR-V7 expression levels in whole blood were detectable in 18% (15/85) of patients. No patient with high AR-V7 expression achieved a PSA response, and AR-V7 status was an independent predictor of PSA response in multivariable logistic regression analysis (p = 0.03). High AR-V7 expression was associated with shorter PSA-PFS (median 2.4 vs 3.7 mo; p < 0.001), shorter clinical PFS (median 2.7 vs 5.5 mo; p < 0.001), and shorter OS (median 4.0 vs. 13.9 mo; p < 0.001). On multivariable Cox regression analysis, high AR-V7 expression remained an independent predictor of shorter PSA-PFS (hazard ratio [HR] 7.0, 95% confidence interval [CI] 2.3–20.7; p < 0.001), shorter clinical PFS (HR 2.3, 95% CI 1.1–4.9; p = 0.02), and shorter OS (HR 3.0, 95% CI 1.4–6.3; p = 0.005). Testing of AR-V7 mRNA levels in whole blood is a simple and promising approach to predict poor treatment outcome in mCRPC patients receiving abiraterone or enzalutamide. We established a method for determining AR-V7 status in whole blood. This test predicted treatment resistance in patients with metastatic castration-resistant prostate cancer undergoing treatment with abiraterone or enzalutamide. Prospective validation is needed before application to clinical practice." @default.
- W2750528063 created "2017-08-31" @default.
- W2750528063 creator A5002762582 @default.
- W2750528063 creator A5003688542 @default.
- W2750528063 creator A5010135926 @default.
- W2750528063 creator A5024163450 @default.
- W2750528063 creator A5024468140 @default.
- W2750528063 creator A5038906134 @default.
- W2750528063 creator A5042524864 @default.
- W2750528063 creator A5049214624 @default.
- W2750528063 creator A5057035995 @default.
- W2750528063 creator A5067456208 @default.
- W2750528063 creator A5068920358 @default.
- W2750528063 creator A5087926275 @default.
- W2750528063 creator A5089218170 @default.
- W2750528063 date "2017-11-01" @default.
- W2750528063 modified "2023-10-14" @default.
- W2750528063 title "AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide" @default.
- W2750528063 cites W1755643198 @default.
- W2750528063 cites W1844925317 @default.
- W2750528063 cites W2055346449 @default.
- W2750528063 cites W2081562657 @default.
- W2750528063 cites W2099066165 @default.
- W2750528063 cites W2110534364 @default.
- W2750528063 cites W2131109308 @default.
- W2750528063 cites W2139248078 @default.
- W2750528063 cites W2148643283 @default.
- W2750528063 cites W2156923287 @default.
- W2750528063 cites W2166918329 @default.
- W2750528063 cites W2167331614 @default.
- W2750528063 cites W2168083201 @default.
- W2750528063 cites W2181283187 @default.
- W2750528063 cites W2476122439 @default.
- W2750528063 cites W2479766819 @default.
- W2750528063 cites W2491436916 @default.
- W2750528063 cites W2505088672 @default.
- W2750528063 cites W2518042319 @default.
- W2750528063 cites W2527109958 @default.
- W2750528063 cites W2530715453 @default.
- W2750528063 cites W2540537925 @default.
- W2750528063 cites W2564702165 @default.
- W2750528063 cites W2891716129 @default.
- W2750528063 cites W3147725646 @default.
- W2750528063 cites W913623683 @default.
- W2750528063 doi "https://doi.org/10.1016/j.eururo.2017.07.024" @default.
- W2750528063 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28818355" @default.
- W2750528063 hasPublicationYear "2017" @default.
- W2750528063 type Work @default.
- W2750528063 sameAs 2750528063 @default.
- W2750528063 citedByCount "79" @default.
- W2750528063 countsByYear W27505280632017 @default.
- W2750528063 countsByYear W27505280632018 @default.
- W2750528063 countsByYear W27505280632019 @default.
- W2750528063 countsByYear W27505280632020 @default.
- W2750528063 countsByYear W27505280632021 @default.
- W2750528063 countsByYear W27505280632022 @default.
- W2750528063 countsByYear W27505280632023 @default.
- W2750528063 crossrefType "journal-article" @default.
- W2750528063 hasAuthorship W2750528063A5002762582 @default.
- W2750528063 hasAuthorship W2750528063A5003688542 @default.
- W2750528063 hasAuthorship W2750528063A5010135926 @default.
- W2750528063 hasAuthorship W2750528063A5024163450 @default.
- W2750528063 hasAuthorship W2750528063A5024468140 @default.
- W2750528063 hasAuthorship W2750528063A5038906134 @default.
- W2750528063 hasAuthorship W2750528063A5042524864 @default.
- W2750528063 hasAuthorship W2750528063A5049214624 @default.
- W2750528063 hasAuthorship W2750528063A5057035995 @default.
- W2750528063 hasAuthorship W2750528063A5067456208 @default.
- W2750528063 hasAuthorship W2750528063A5068920358 @default.
- W2750528063 hasAuthorship W2750528063A5087926275 @default.
- W2750528063 hasAuthorship W2750528063A5089218170 @default.
- W2750528063 hasConcept C121608353 @default.
- W2750528063 hasConcept C126322002 @default.
- W2750528063 hasConcept C126894567 @default.
- W2750528063 hasConcept C143998085 @default.
- W2750528063 hasConcept C151956035 @default.
- W2750528063 hasConcept C207103383 @default.
- W2750528063 hasConcept C2776551883 @default.
- W2750528063 hasConcept C2779013556 @default.
- W2750528063 hasConcept C2780192828 @default.
- W2750528063 hasConcept C2781406297 @default.
- W2750528063 hasConcept C44249647 @default.
- W2750528063 hasConcept C50382708 @default.
- W2750528063 hasConcept C61238886 @default.
- W2750528063 hasConcept C61367390 @default.
- W2750528063 hasConcept C71924100 @default.
- W2750528063 hasConceptScore W2750528063C121608353 @default.
- W2750528063 hasConceptScore W2750528063C126322002 @default.
- W2750528063 hasConceptScore W2750528063C126894567 @default.
- W2750528063 hasConceptScore W2750528063C143998085 @default.
- W2750528063 hasConceptScore W2750528063C151956035 @default.
- W2750528063 hasConceptScore W2750528063C207103383 @default.
- W2750528063 hasConceptScore W2750528063C2776551883 @default.
- W2750528063 hasConceptScore W2750528063C2779013556 @default.
- W2750528063 hasConceptScore W2750528063C2780192828 @default.
- W2750528063 hasConceptScore W2750528063C2781406297 @default.
- W2750528063 hasConceptScore W2750528063C44249647 @default.
- W2750528063 hasConceptScore W2750528063C50382708 @default.